Please assess the completion status of the following clinical trial:

Trial Title: A Multinational Study to Evaluate the Effects of a 28-Day Oral Contraceptive on Hemostatic Parameters in Healthy Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Premenopausal, non-pregnant, non-lactating women age 18-40 years old~* Body Mass Index (BMI) ≥18 kg/m² and \<30 kg/m²~* Regular spontaneous menstrual cycle~* Others as dictated by FDA-approved protocol~Exclusion Criteria:~* Any condition which contraindicates the use of combination oral contraceptives~* Any history of, or active, deep vein thrombosis, pulmonary embolism, or arterial thromboembolic disease within one year of screening~* Thrombophlebitis or thromboembolic disorders; known or suspected clotting disorders; thrombogenetic valvulopathies or rhythm disorders~* Others as dictated by FDA-approved protocol

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- Treatment I: (DR-102) (Type: EXPERIMENTAL): 21 days of combination active pills (containing 150 mcg desogestrel \[DSG\]/20 mcg ethinyl estradiol \[EE\]), followed by 7 days of 10 mcg EE, taken orally for 6 consecutive 28-day cycles
- Treatment II (Type: ACTIVE_COMPARATOR): 21 days combination active pills (containing 150 mcg DSG/20 mcg EE), taken orally and followed by 7 days of no treatment for a total of 6 consecutive 28-day cycles

Based on this trial design, predict the completion outcome and termination type (if applicable).